Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility.

Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlén SE, Greco D, Söderhäll C, Scheynius A, Kere J. · 2012

Read Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. by Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlén SE, Greco D, Söderhäll C, Scheynius A, Kere J. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3405143.txt.

Introduction

Reinius and colleagues warned in 2012 that DNA methylation measured from whole blood can mislead, because blood is a mixture of cell types. Each white cell lineage carries its own methylation pattern. If illness studies compare blood samples with different cell mixes, apparent disease signals may just be cell counts in disguise.

In healthy male donors, the team profiled whole blood, its two great cell families, and seven purified lineages. For most immune-related genes studied, at least one site differed sharply between the two families. Some control-region sites even flipped direction between cell types. Disease studies, they conclude, must account for cell mix before claiming a methylation link to illness.

Catalog record

CREATORReinius LE, Acevedo N, Joerink M, Pershagen G, Dahlén SE, Greco D, Söderhäll C, Scheynius A, Kere J.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3405143

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Differential DNA Methylation in Purified Human Blood Cells: Implications for Cell Lineage and Studies on Disease Susceptibility By Lovisa E. Reinius, Nathalie Acevedo, Maaike Joerink, Göran Pershagen, Sven-Erik Dahlén, Dario Greco, Cilla Söderhäll, Annika Scheynius, Juha Kere, Angela H. Ting Published in: PLoS ONE DOI: 10.1371/journal.pone.0041361 ABSTRACT Methylation of cytosines at CpG sites is a common epigenetic DNA modification that can be measured by a large number of methods, now even in a genome-wide manner for hundreds of thousands of sites. The application of DNA methylation analysis is becoming widely popular in complex disorders, for example, to understand part of the “missing heritability”. The DNA samples most readily available for methylation studies are derived from whole blood. However, blood consists of many functionally and developmentally distinct cell populations in varying proportions. We studied whether such variation might affect the interpretation of methylation studies based on whole blood DNA. We found in healthy male blood donors there is important variation in the methylation profiles of whole blood, mononuclear cells, granulocytes, and cells from seven selected purified lineages. CpG methylation between mononuclear cells and granulocytes differed for 22% of the 8252 probes covering the selected 343 genes implicated in immune-related disorders by genome-wide association studies, and at least one probe was differentially methylated for 85% of the genes, indicating that whole blood methylation results might be unintelligible. For individual genes, even if the overall methylation patterns might appear similar, a few CpG sites in the regulatory regions may have opposite methylation patterns (i.e., hypo/hyper) in the main blood cell types. We conclude that interpretation of whole blood methylation profiles should be performed with great caution and for any differences implicated in a disorder, the differences resulting from varying proportions of white blood cell types should be considered. INTRODUCTION DNA methylation is the covalent addition of a methyl group in the position 5 of a cytosine (C) when this nucleotide occurs next to a guanine (G) forming a CpG site. There are around 28 million CpG sites in the human genome. Depending on the chromosomal region, cell type, developmental stage, alleles and parent-of-origin, a CpG site can be methylated, unmethylated or hemi-methylated. DNA methylation is involved in regulation of transcriptional repression and gene silencing. Together with other epigenetic mechanisms, DNA methylation functions as a switch that turns relevant genes on and off, a mechanism that is crucial in development, differentiation and homeostasis [1]. Certain CpG sites are highly methylated in hematopoietic progenitors but become unmethylated during differentiation [2], [3], [4]. There is also a small number of genes that gain cell specific methylation when the embryonic stem (ES) cells differentiate into the three germ layers [5]. The search for those methylated and/or unmethylated CpG sites that may categorize tissues and cell populations have been under extensive research for more than two decades [6], [7]. It is known that cell specific DNA methylation patterns convey “cell memory”, which is transmitted to the progeny by mitosis [8]. Therefore, every differentiated cell type has CpG sites that are specifically methylated or unmethylated for that specific lineage but not for others [2], [9]. There is currently extensive research ongoing aiming at the identification of specific changes in DNA methylation that may contribute to human diseases. Alterations in DNA methylation have been shown to cause monogenic disease such as Rett syndrome [10], and mediate genomic instability, silencing of tumor-suppressor genes and hyper-methylation of CpG island shores that may lead to the inception and progression of cancer [11]. Results of genome wide association studies together with the marked increase in the prevalence of several complex diseases during the last decades, for example asthma and allergy, suggests that other mechanisms such as epigenetics, including DNA methylation, may also be involved [12], [13]. These hypotheses have been supported by the differential effect of genetic polymorphisms depending on parent-of-origin [14], DNA methylation differences in disease-discordant monozygotic twins [15], [16], [17], differences in DNA methylation related to environmental exposures [18], [19], and DNA methylation differences in affected versus non-affected tissues [20], [21]. Given the limitations to obtain large number of samples from affected tissues, blood is an attractive, easy and available source of DNA. Studies suggest that DNA methylation differences can be detected in the blood of patients with cancer, even for solid tumors [22], [23], [24]. There is an increasing number of publications comparing differences in DNA methylation in whole blood between cases and controls for complex diseases [25], [26], [27], [28]. Topperoff et al found a specific methylation pattern in whole blood from patients with Type 2 diabetes that could be detected prior the onset of the disease [27]. In addition, differences in DNA methylation were identified in leukocytes of mothers having children with congenital heart defects [25]. Importantly, cell heterogeneity may act as a confounder when measuring DNA methylation in whole blood and the possibility to adjust for differential cell counts is being explored [27]. However, it is still unclear whether this strategy suffices to correct for inter-individual variation, lineage relationships (myeloid versus lymphoid), and potential effects of prominent methylation differences in less frequent cell populations (e.g. B cells, eosinophils, T regulatory cells). The aims of this study were 1) to identify differentially methylated CpG sites globally in purified blood cells in connection with their genomic distribution; 2) to identify genes harboring the differentially methylated CpG sites and their connections with cell lineage and functions; and 3) to compare the DNA methylation profiles in a selection of candidate genes for complex inflammatory diseases among blood cell populations. RESULTS General description of cell populations Six healthy male blood donors, age 38±13.6 years, were included in the study. From each individual, global DNA methylation levels were analyzed in whole blood, peripheral blood mononuclear cells (PBMC) and granulocytes as well as for seven isolated cell populations (CD4+ T cells, CD8+ T cells, CD56+ NK cells, CD19+ B cells, CD14+ monocytes, neutrophils, and eosinophils, Figure 1). The differential cell count in whole blood was similar for all six donors as well as the purities of sorted cell populations as determined by flow cytometry (Figure S1, Table S1). The purities based on surface cell markers ranged from lowest 81.8±18.8% for eosinophils to highest 97.8±1.7% for neutrophils (Table S2). [Figure: Schematic presentation of the isolation protocol and purity of the cell populations as measured by flow cytometry.Peripheral blood mononuclear cells (PBMC) and granulocytes were obtained by density gradient centrifugation and seven cell populations were purified by magnetic sorting. Upper panel shows forward and side scatter which confirmed cell morphology and granularity. The lower panel shows the overlay of cell surface markers for all the six donors. The purities of the cell populations were highly similar among all the six donors. Th cells = CD4+ T cells, Tc cells = CD8+ T cells, NK cells = CD56+ NK cells, B cells = CD19+ B cells, Monocytes = CD14+ monocytes. Data analyses are based on the comparison of all cell populations to whole blood.] DNA methylation differences reflect cell lineages rather than inter-individual differences Global DNA methylation was analyzed using the Illumina Infinium 450K microarray platform [29]. When comparing all the cell populations against each other, there were large variations in the number of differentially methylated CpG sites

Read the complete text